Many Oncology Drugs Approved for Genomic Indications Not Studied for Overall Survival Outcomes
Overall survival data were available for about half of the drugs.
Overall survival data were available for about half of the drugs.
Investigators assessed rates of colorectal cancer screening participation in the time periods before and after introduction of multi-target stool DNA tests.
There was a significant increase in out-of-pocket costs for all 4 cancer types studied.
The study showed no significant differences in outcomes by age.
About 31% of the articles analyzed contained information classified as harmful.
Phase 3 results refute findings from retrospective studies.
The results suggest a link, but more research is needed.
Some nongenetic risk factors for late-onset colorectal cancer may not be relevant for early-onset disease.
Having a first-degree relative with colorectal polyps may increase a person’s risk of developing colorectal cancer, indicating that earlier screening is warranted.
Colorectal cancer rates have been rising in younger people for years, and screenings are now recommended to begin at a younger age. How much and why have rates been increasing, and what preventive steps can you teach these patients to lessen their risk?